Tech Company Financing Transactions
ThirtyFiveBio Funding Round
On 4/15/2025, ThirtyFiveBio raised funding from AbbVie Biotech Ventures and Canaan Partners.
Transaction Overview
Company Name
Announced On
4/15/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to support the continued development of the its GPR35 inhibitor program, which is currently advancing through preclinical development, including investigational new drug (IND)-enabling studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Milton Park Innovation Centre, 99 Park Drive, Milton Park
Abingdon, OX14 4RY
UK
Abingdon, OX14 4RY
UK
Phone
Website
Email Address
Overview
Applying proprietary understanding to guide a precision medicine approach; We're in business to deliver novel therapeutic opportunities to patients with serious digestive system disorders where there exists a high unmet clinical need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Westcott
Browse more venture capital transactions:
Prev: 4/15/2025: Homemove venture capital transaction
Next: 4/15/2025: Corvic AI venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs